- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01202591
Safety and Efficacy of AZD4547 in Combination With Fulvestrant vs. Fulvestrant Alone in ER+ Breast Cancer Patients (GLOW)
January 13, 2016 updated by: AstraZeneca
A Randomised Double-blind Phase IIa Study (With Combination Safety Run-in) to Assess the Safety and Efficacy of AZD4547 in Combination With Fulvestrant vs. Fulvestrant Alone in ER+ Breast Cancer Patients With FGFR1 Polysomy or Gene Amplification Who Have Progressed Following Treatment With Prior Endocrine Therapy (Adjuvant or First-line Metastatic) (GLOW)
The purpose of this study is to assess the safety and effectiveness of AZD4547 in combination with fulvestrant vs. fulvestrant alone in ER+ breast cancer patients with FGFR1 polysomy (FISH4/5) or gene amplification (FISH 6)
Study Overview
Status
Completed
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
127
Phase
- Phase 2
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Leuven, Belgium
- Research Site
-
Namur, Belgium
- Research Site
-
-
-
-
-
Brno, Czech Republic
- Research Site
-
Praha 4, Czech Republic
- Research Site
-
-
-
-
-
Villejuif Cedex, France
- Research Site
-
-
-
-
-
Erlangen, Germany
- Research Site
-
München, Germany
- Research Site
-
Rostock, Germany
- Research Site
-
-
-
-
-
Budapest, Hungary
- Research Site
-
Kaposvár, Hungary
- Research Site
-
Nyíregyháza, Hungary
- Research Site
-
Szeged, Hungary
- Research Site
-
-
-
-
-
Genova, Italy
- Research Site
-
Lido di Camaiore, Italy
- Research Site
-
Roma, Italy
- Research Site
-
-
-
-
-
Cluj Napoca, Romania
- Research Site
-
-
-
-
-
Dundee, United Kingdom
- Research Site
-
London, United Kingdom
- Research Site
-
Manchester, United Kingdom
- Research Site
-
Oxford, United Kingdom
- Research Site
-
Sutton, United Kingdom
- Research Site
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 99 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Female
Description
Inclusion Criteria:
- Post-menopausal women (either through bilateral oophorectomy or amenorrhoeic for 24 months)
- Histological confirmation of Breast Cancer with documented ER+ receptor status
- Safety run-in: Relapsing during/within 12 months of completion of a single regimen of adjuvant endocrine therapy with non-steroidal AI and/ tamoxifen or progression following 1st line endocrine therapy with non-steroidal AL
- Rand phase IIa: Received at least 1 prior endocrine therapy in the metastatic setting or have relapsed during/ within 6 months of completion of adjuvant endocrine therapy (either non-steroidal AI or tamoxifen or a combination of both). Chemotherapy administered in the adjuvant setting is permitted.
- Rand phase IIa: Mandatory provision of tumour sample to confirm FGFR1 polysomy or gene amplification. At least one measurable lesion that can be accurately assessed by CT/MRI/x-ray at baseline and follow up visits
Exclusion Criteria:
- Prior exposure to exemestane (safety run-in) / fulvestrant (randomized phase IIa), or any agent known to inhibit FGFRs.
- More than 1 prior regimen of chemotherapy for breast cancer
- ECG recordings that demonstrate significant abnormalities in cardiac rate, rhythm or conduction
- History of hypersensitivity to active or inactive excipients of AZD4547 or exemestane (safety run-in ) or fulvestrant (Randomized phase), including castor oil, or drugs with a similar chemical structure or class to AZD4547 or exemestane or fulvestrant.
- Randomized phase IIa: bleeding/blood clotting conditions that would prevent the administration of the fulvestrant injection into the buttocks
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: AZD4547 + exemestane
Safety run-in: AZD4547 plus exemestane
|
Tablet oral twice daily
Tablet oral once daily
|
Experimental: AZD4547 + fulvestrant
A Randomised phase IIa: AZD4547 plus fulvestrant
|
Tablet oral twice daily
A monthly intramuscular injection of a depot formulation with a loading dose 14 days after initial administration
|
Placebo Comparator: Placebo + fulvestrant
Randomised phase IIa: Matching placebo plus fulvestrant
|
A monthly intramuscular injection of a depot formulation with a loading dose 14 days after initial administration
Tablet oral twice daily
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Safety and Tolerability in Terms of Number of Patients With Adverse Events (Serious and Non-serious)
Time Frame: 3 years, 10 months (Adverse events recorded from patient screening to discontinuation plus 28 days safety follow-up).
|
3 years, 10 months (Adverse events recorded from patient screening to discontinuation plus 28 days safety follow-up).
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: Donal Landers, AstraZeneca
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
December 1, 2010
Primary Completion (Actual)
September 1, 2014
Study Completion (Actual)
October 1, 2014
Study Registration Dates
First Submitted
September 14, 2010
First Submitted That Met QC Criteria
September 14, 2010
First Posted (Estimate)
September 16, 2010
Study Record Updates
Last Update Posted (Estimate)
February 11, 2016
Last Update Submitted That Met QC Criteria
January 13, 2016
Last Verified
January 1, 2016
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Skin Diseases
- Neoplasms
- Neoplasms by Site
- Breast Diseases
- Breast Neoplasms
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antineoplastic Agents
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Antineoplastic Agents, Hormonal
- Hormone Antagonists
- Aromatase Inhibitors
- Steroid Synthesis Inhibitors
- Estrogen Antagonists
- Estrogen Receptor Antagonists
- Fulvestrant
- Exemestane
Other Study ID Numbers
- D2610C00003
- 2010-021220-10 (EudraCT Number)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on FGFR Inhibition, Pharmacokinetics, Biomarkers
-
Dr. R. Pfleger Chemische Fabrik GmbHCompletedPharmacokinetics | Drug Interaction Potentiation | Inhibition Enzyme
Clinical Trials on AZD4547
-
National Cancer Institute (NCI)CompletedHematopoietic and Lymphoid Cell Neoplasm | Advanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Refractory Plasma Cell MyelomaUnited States
-
AstraZenecaCompletedCancer | Advanced Solid MalignanciesJapan
-
AstraZenecaTerminatedCancer | Advanced Solid MalignanciesUnited States, Italy, United Kingdom, France, Germany, Spain, Netherlands
-
Abbisko Therapeutics Co, LtdRecruitingUrothelial CarcinomaChina
-
Abbisko Therapeutics Co, LtdCompleted
-
Southwest Oncology GroupNational Cancer Institute (NCI)CompletedRecurrent Squamous Cell Lung Carcinoma | Stage IV Squamous Cell Lung Carcinoma AJCC v7 | FGFR1 Gene Amplification | FGFR2 Gene Amplification | FGFR2 Gene Mutation | FGFR3 Gene Mutation | FGFR1 Gene Mutation | FGFR3 Gene AmplificationUnited States, Canada
-
Abbisko Therapeutics Co, LtdRecruitingUrothelial CarcinomaChina
-
AstraZenecaTerminatedGastric Cancer | Gastro-oesophageal Junction CancerBulgaria, Czech Republic, Italy, Korea, Republic of, Spain, United Kingdom, Hungary, Romania, Ukraine, Belgium, Canada, Germany, Taiwan, India, Japan, France
-
ECOG-ACRIN Cancer Research GroupNational Cancer Institute (NCI)CompletedRecurrent Non-small Cell Lung Cancer | Squamous Cell Lung CancerUnited States
-
AstraZenecaActive, not recruitingMuscle Invasive Bladder CancerSpain, United States, Canada, France, United Kingdom